Market news
TypeAll
SortNewest
Assets
IRON
Sep 10Investing.com
IRON
Sep 10Investing.comIRON
Sep 10Investing.comIRON
Sep 10Investing.comIRON
Sep 9Investing.comIRON
Wedbush Raises Price Target on Disc Medicine to $100 From $88, Keeps Outperform Rating
Disc Medicine (IRON) has an average rating of buy and mean price target of $101.58, according to ana
Sep 2Yahoo FinanceIRON
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from...
Aug 31Barchart.comIRON
Aug 27Investing.comIRON
Aug 19Investing.comIRON
Aug 18MorningstarIRON
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making
Aug 17Yahoo FinanceIRON
Aug 14Investing.comIRON
Aug 7Investing.comIRON
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response;...
Jul 30Barchart.comIRON
Jul 21Seeking AlphaIRON
Jul 15Investing.comIRON
Jul 14Investing.comIRON
Jul 9Investing.comIRON
This is the newest page. Registered accounts read further back.